Search

Supplemental material, sj-docx-1-jet-10.1177_15266028231157639 for Systematic Review and Meta-Analysis of Ex-Situ and In-Situ Fenestrated Stent-Grafts for Endovascular Repair of Aortic Arch Pathologies by Mourad Boufi, Georgiana Alexandru, Myriam Tarzi, Molka Zlitni, Houda Taghi and Anderson D. Loundou in Journal of Endovascular Therapy

Supplemental material, sj-docx-1-jet-10.1177_15266028231157639 for Systematic Review and Meta-Analysis of Ex-Situ and In-Situ Fenestrated Stent-Grafts for Endovascular Repair of Aortic Arch Pathologies by Mourad Boufi, Georgiana Alexandru, Myriam Tarzi, Molka Zlitni, Houda Taghi and Anderson D. Loundou in Journal of Endovascular Therapy

Objective The present study analyzes nutrition support in a group of patients undergoing colorectal surgery managed by nutritional requirement software compared to a group of consecutive patients undergoing colorectal surgery with conventional nutrition Materials and Methods A total of 485 patients were treated between January 2000 and January 2013 with colorectal resection. Outcomes (mortality, morbidity according to Clavien classification, length of hospital stay, type of colorectal disease) in a group of patients who received nutrition support through software (SG) were compared to those in a previous series, control group (CG) with conventional nutrition support Results Of the patients, 59.6% were men and the median age of the population was 68.2 years (range, 19–95 years), with no difference between the 2 groups. There were significantly more malnourished patients in the SG group (SG 63.8% versus 45.2% CG; P < 0.0001). The overall mortality was 2.1% lower in the SG group, but without a significant difference (SG 0.7% versus 2.7% CG). There were more severe stage III to IV complications according to Clavien classification in the SG group (SG 10.7 GC versus 17% NS), with significantly greater collections (SG 8% versus 16.9% CG; P = 0.015) and greater anastomotic leaks (SG 4% versus 13.9% CG; P < 0.001). The median hospital stay was lower in the SG group (SG 12 days versus 15 days CG; P = 0.049). Conclusion The proposed software could contribute to optimizing the strategy of nutritional support in hospitalized patients.

Additional file 2. Statistical analysis plan.

Additional file 3: Table S3. Patients outcomes according to treatment with dexamethasone and rescue immunosuppressive therapy.

Additional file 1: Table S1. Characteristics of recurrent VAP episodes according to dexamethasone treatment.

Additional file 1. Protocol.

Additional file 3: Table S1. Microorganisms Responsible for Bacteremia/Fungemia Post-Randomization According to Study Group. Table S2. Microorganisms other than viruses Responsible for Ventilator-Associated Pneumonia Post-Randomization According to Study Group. Figure S1. Temperature Kinetics from Randomization to Day 14 According to Study Group. Figure S2. White Blood-Cell–Count Kinetics from Randomization to Day 14 according to Study Group. Figure S3. Platelet-Count Kinetics from Randomization to Day 14 According to Study Group. Figure S4. Creatinine-Level Kinetics from Randomization to Day 14 According to Study Group. Figure S5. Kinetics of Radiologic Score 1 from Randomization to Day 14 According to Study Group. Figure S6. Evolution of Modified Clinical Pulmonary Infection Score (mCPIS) 2 from Randomization to Day 14 According to Study Group. Figure S7. Metanalyses from randomized clinical trials evaluating the effects of prophylactic or preemptive ganciclovir/valganciclovir on mortality at day 28, hospital mortality and ventilator-free days at day 28 (VFD28).

BACKGROUND “Biopsy-only” glioblastoma is associated with a heterogeneous functional and survival outcome. It is an understudied group of patients which has been reported to represent 21% of histologically confirmed GBM in the US National Cancer Data Base. Pattern of care included radiotherapy-temozolomide (RT-TMZ) completed in 15% of patients, any other form of oncologic treatment in 60%, and supportive care alone in 25% of patients. Our objective was to explore treatment and prognosis of BO-GBM. MATERIAL AND METHODS Patients with BO-GBM included in a prospective regional glioma SIRIC cohort in 2014-2017 were retrospectively reviewed for patient characteristics, MRI finding, treatment allocation and delivery. PFS and OS were analyzed. RESULTS Of 535 patients included in the cohort, 449 patients were included at initial surgery, of which 158 patients (35%) underwent biopsy only. Of 158 patients, 18 were excluded for missing data leaving 139 patients for the present analysis. Fifty-four (39%) were referred to RT-TMZ, 68 (49%) considered unfitted for RT received chemotherapy upfront (CT-UF), 17 (12%) were referred to palliative care. Groups differed at baseline for age (mean 60 and 68 years, for RT-TMZ, CT-UF respectively); KPS (70, 60 for RT-TMZ, CT-UF); mean tumor surface (793, 1420 mm2 for RT-TMZ, CT-UF); and tumor extension (bilateral in 6.4% and 29.3% for RT-CT and CT-UF respectively). Median OS was 14 months (95% CI, 9.65-18.71) and 8 months (95% CI, 4.62-7.67) for RT-TMZ, CT-UF respectively. CONCLUSION Inoperable GBM constitute a large and heterogeneous population in which one third of patients are amenable to standard of care, with survival outcome close to the one of patients who underwent surgery. Patients considered unfit for RT-CT at diagnosis exhibit a poor survival outcome. Thus, reliable criteria are needed to help selecting patients for adequate treatment while new strategies are warranted for BO-GBM unfit for RT.

Additional file 5: Table S5. Other information recorded during the interview with the ICU physician.

Additional file 1: Table S1. Evolution of SOFA score and respiratory parameters from day one (D1) to day 15 (D15).

Additional file 1: Table S1. Clinical outcomes according to anti-viral treatment.

Additional file 3: Table S3. Indexes assessed by the WAIS-IV.

Additional file 2: Table S2. Differences among the two groups according to the threshold used to define a cognitive impairment.

Additional file 4: Table S4. Health-related quality of life assessed by the SF-36 score.

International audience; Lung transplantation (LTx) is a valid therapeutic option for selected patients with end-stage lung disease. HLA-E seems to play a major role in the immune response to different viral infections and to affect transplantation outcome, in Hematopoietic Stem Cell Transplantation, for example. Two nonsynonymous alleles, HLA-E(⁎)01:01 and HLA-E(⁎)01:03, have functional differences, involving relative peptide affinity, cell surface expression, and potential lytic activity of NK cells. The aim of this retrospective study was to determine the impact of these two alleles for LTx recipients on anti-HLA alloimmunization risk, overall survival, and chronic rejection (CLAD). HLA-E was genotyped in 119 recipients who underwent LTx from 1998 to 2010 in a single transplantation center. In univariate analysis, both HLA-E homozygous states were associated with impaired overall survival compared to heterozygous HLA-E alleles (p = 0.01). In multivariate analysis, HLA-E(⁎)01:03 allele showed increased CLAD occurrence when compared to homozygous HLA-E(⁎)01:01 status (HR: 3.563 (CI 95%, 1.016-12), p = 0.047). HLA-E allele did not affect pathogen infection or the production of de novo DSA. This retrospective study shows an uninvestigated, deleterious association of HLA-E alleles with LTx and requires verification using a larger cohort.

Kaplan-Meier graphs of the probability of survival over 90Â days after inclusion of patients with ARDS according to Pplat,rs and Crs. The curves were compared by using the log rank test. (PPTX 92 kb)

Multivariate Cox regression analysis for factors on day 1 including mechanical power associated with ARDS mortality at day 90. (DOC 33 kb)

Adjusted probability of survival derived from the Cox model according Pplat,rs (A) and Crs (B). (PPTX 90 kb)

Multivariate Cox regression analysis for factors on day 1 including a couple of collinear variables associated with ARDS mortality at day 90. (DOCX 19 kb)

Multivariate Cox regression analysis for factors on day 1 including a couple of collinear variables associated with ARDS mortality at day 90. (DOCX 19 kb)

Multivariate Cox regression analysis for factors on day 1 including compliance of the respiratory system associated with ARDS mortality at day 90. (DOC 33 kb)

Adjusted probability of survival derived from the Cox model according Pplat,rs (A) and Crs (B). (PPTX 90 kb)

Adjusted probability of survival derived from the Cox model according to Î Prs (A) and mechanical power (B). (PPTX 89 kb)

Multivariate Cox regression analysis for factors on day 1 including compliance of the respiratory system associated with ARDS mortality at day 90. (DOC 33 kb)

Kaplan-Meier graphs of the probability of survival over 90Â days after inclusion of patients with ARDS according to Pplat,rs and Crs. The curves were compared by using the log rank test. (PPTX 92 kb)

Multivariate Cox regression analysis for factors on day 1 including plateau pressure associated with ARDS mortality at day 90. (DOC 33 kb)

Adjusted probability of survival derived from the Cox model according to Î Prs (A) and mechanical power (B). (PPTX 89 kb)

Multivariate Cox regression analysis for factors on day 1 including plateau pressure associated with ARDS mortality at day 90. (DOC 33 kb)

International audience